These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16249350)

  • 1. Antibody-based therapies for colorectal cancer.
    Chung KY; Saltz LB
    Oncologist; 2005 Oct; 10(9):701-9. PubMed ID: 16249350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical evaluation of current treatments in metastatic colorectal cancer.
    Venook A
    Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of colorectal cancer.
    Veronese ML; O'Dwyer PJ
    Eur J Cancer; 2004 Jun; 40(9):1292-301. PubMed ID: 15177487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
    Kris MG
    Oncologist; 2005 Oct; 10 Suppl 2():23-9. PubMed ID: 16272456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
    Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
    Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
    Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
    Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.
    Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):665-83. PubMed ID: 17064225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
    Hoff PM
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):17-21. PubMed ID: 15696026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for colon cancer.
    He AR; Marshall J
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):555-61. PubMed ID: 16167038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on novel therapeutic agents for cervical cancer.
    del Campo JM; Prat A; Gil-Moreno A; Pérez J; Parera M
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S72-6. PubMed ID: 18544460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
    Hoff PM; Ellis LM; Abbruzzese JL
    Oncology (Williston Park); 2004 May; 18(6):736-41; discussion 742, 745-6. PubMed ID: 15214593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
    Nygren P; Sørbye H; Osterlund P; Pfeiffer P
    Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.